Get the Stockscreener App
26.69
0.37%
-0.10
After Hours:
26.69
Lenz Therapeutics Inc stock is traded at $26.69, with a volume of 98,507.
It is down -0.37% in the last 24 hours and down -2.09% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$26.79
Open:
$27
24h Volume:
98,507
Relative Volume:
0.64
Market Cap:
$734.00M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-4.7684
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
+4.75%
1M Performance:
-2.09%
6M Performance:
+13.33%
1Y Performance:
+0.00%
1-Day Range:
$26.52
$27.12
1-Week Range:
$24.60
$27.46
52-Week Range:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
26.69 | 734.00M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Target Price from Brokerages - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Trading 8% HigherWhat's Next? - MarketBeat
Leerink Partnrs Has Negative Outlook of LENZ FY2025 Earnings - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by Analysts - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5.1%What's Next? - MarketBeat
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings - Defense World
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Citeline News & Insights
Myopia Pipeline 2024: Detailed Clinical Trials - openPR
LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday - Defense World
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight - EIN News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat
Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat
Trio-Tech International (NYSE:TRT) Coverage Initiated by Analysts at StockNews.com - Defense World
Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Lenz Therapeutics New Becomes Oversold (LENZ) - Nasdaq
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.1% Following Analyst Downgrade - Defense World
Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
Head to Head Contrast: Allied Resources (ALOD) versus Its Peers - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
SkyWater Technology, Inc. (NASDAQ:SKYT) Shares Purchased by Barclays PLC - Defense World
NI Holdings, Inc. (NASDAQ:NODK) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Acquires 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Neumora plummets on depression drug data - BioPharma Dive
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Raises Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat
Jane Street Group LLC Cuts Stock Holdings in Jpmorgan Betabuilders U.S. Treasury Bond 20+ Year ETF (NYSEARCA:BBLB) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3%Should You Buy? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1% – What’s Next? - Defense World
Wellington Management Group LLP Invests $585,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1%Time to Sell? - MarketBeat
BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Presbyopia Therapeutics Market Size was highest in the US among the 7MM, was ~USD 8,039 million, and is expected to increase by 2034 | DelveInsight - Barchart
Presbyopia Therapeutics Market Size was highest in the US among - openPR
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):